Track market-moving stories before they get noisy

Key Takeaways WELL beat Q1 estimates with $1.47 normalized FFO per share and $3.35 billion in revenues.Welltower's SHO portfolio posted 22.1% SSNOI growth as occupancy climbed to 89.0%.WELL raised 2026 normalized FFO guidance to $6.21-$6.35 and held $11.1 billion in liquidity. Welltower Inc. (WELL - Free Report) reported first-quarter 2026 normalized funds from operations (FFO) of $1.47 per share, topping the Zacks Consensus Estimate of $1.45 by 1.38%. Total revenues of $3.35 billion beat the consensus mark of $3.23 billion by 3.68% and rose 38.3% year over year.

Results reflected continued strength in the seniors housing operating (SHO) portfolio, where same-store net operating income (SSNOI) growth remained robust and occupancy gains supported margin recovery. Total portfolio year-over-year SSNOI increased 16.4% in the quarter, led by SHO performance.

WELL’s Revenue Mix Tilted Toward Resident FeesWelltower’s top line was driven primarily by resident fees and services, reflecting the scale of its operating exposure. Resident fees and services rose 49.1% year over year to $2.78 billion in the first quarter, forming the bulk of total revenues.

Other revenue lines were comparatively smaller and moved in a mixed fashion. Rental income slipped 1.7% year over year to $453.8 million, while interest income increased 13.5% to $70.9 million and other income rose 34% to $46.2 million.

WELL’s SHO Portfolio Drove Operating LeverageWelltower’s SHO portfolio delivered another quarter of outsized SSNOI growth. Same-store revenues rose 9.5% year over year to $1.72 billion, supported by a 370-basis-point occupancy gain to 89.0% in the first quarter of 2026.

Operating leverage showed up in profitability and margins. Same-store operating expenses increased 4.7% to $1.19 billion, well below the pace of revenue growth, lifting SSNOI 22.1% to $531.8 million. SSNOI margin expanded to 30.9% from 27.7% a year ago, a 320-basis-point improvement.

WELL Expanded Capital Deployment While Recycling AssetsCapital allocation remained active. During the first quarter, Welltower completed $3.3 billion of pro rata gross investments and, year to date though April 28, 2026, closed or was under contract to close $10.5 billion of investment activity.

The company also continued to recycle capital through dispositions and loan repayments. In the quarter, it completed $2.8 billion of pro rata dispositions and loan repayments, including $1.4 billion of outpatient medical dispositions, $524 million of sales of long-term/post-acute care properties and $873 million of loan repayments.

WELL Ended Q1 With Low Leverage and Deep LiquidityWELL’s balance sheet position remained a notable support for its external growth strategy. As of March 31, 2026, the company reported Net Debt to Adjusted EBITDA of 2.73x and approximately $11.1 billion of available liquidity, including $4.8 billion of cash and restricted cash plus full capacity under its $6.25 billion line of credit.

The company also highlighted recent financing actions that improved flexibility and reduced refinancing pressure, including the expansion of its senior unsecured revolving credit line and the repayment of $700 million of senior unsecured notes at maturity in April using free cash flow. With leverage low and liquidity substantial, Welltower appears positioned to pursue announced investment pipelines while maintaining balance sheet capacity for additional opportunities.

WELL Raised 2026 Outlook on NOI MomentumManagement lifted 2026 guidance following the first-quarter performance. The company raised its full-year normalized FFO outlook to a range of $6.21-$6.35 per share from its prior range of $6.09-$6.25. The Zacks Consensus Estimate for the same is pegged at $6.22, which stands within the guided range.

WELL’s guidance assumes the average blended SSNOI growth of 12.25-16.00%, comprising 16.5-21.5% growth in Seniors Housing Operating, 3.0-4.0% in Seniors Housing Triple-net, 2.0-3.0% in Outpatient Medical and 2.0-3.0% in Long-Term/Post-Acute Care.

Currently, the company carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Performance of Other REITsVentas, Inc. (VTR - Free Report) delivered first-quarter 2026 normalized FFO per share of 94 cents, beating the Zacks Consensus Estimate of 91 cents by 3.3%. The metric increased 9.3% from 86 cents in the prior-year quarter.

VTR’s revenues came in at $1.66 billion, up 22% year over year and above the Zacks Consensus Estimate of $1.54 billion by 4.58%. Results were powered by the SHOP, while the company ended the quarter with $5.5 billion of liquidity.

Prologis, Inc. (PLD - Free Report) posted first-quarter 2026 core FFO per share of $1.50, up 5.6% from $1.42 a year ago. The figure beat the Zacks Consensus Estimate of $1.48 by 1.49%.

Rental revenues came in at $2.13 billion, increasing 6.9% year over year. The top line also topped the Zacks Consensus Estimate of $2.10 billion, with a 1.12% surprise. PLD’s results were supported by robust leasing activity.

Note: Anything related to earnings presented in this write-up represents FFO, a widely used metric to gauge the performance of REITs.

-

CHICAGO--(BUSINESS WIRE)--Ventas, Inc. (NYSE: VTR) today announced that its Board of Directors has declared a quarterly dividend of $0.52 per common share. The dividend will be payable in cash on July 16, 2026, to stockholders of record as of the close of business on June 30, 2026.

About Ventas

Ventas, Inc. (NYSE: VTR) is an S&P 500 company enabling exceptional environments that benefit a large and growing aging population. With more than 1,400 properties in North America and the United Kingdom, Ventas occupies an essential role in the longevity economy. The Company’s growth is fueled by its approximately 900 senior housing communities, which provide valuable services to residents and enable them to thrive in supported environments. Ventas aims to deliver outsized performance by leveraging its operational expertise, data-driven insights from its Ventas OITM platform, extensive relationships and strong financial position. The Ventas portfolio also includes outpatient medical buildings, research centers and healthcare facilities. Ventas’s seasoned team of talented professionals shares a commitment to excellence, integrity and a common purpose of helping people live longer, healthier, happier lives.

More News From Ventas, Inc.

Back to Newsroom

Ford shares gained on Wednesday as traders continue to lean into optimism about the company’s European product roadmap and its new energy storage push.

Don't forget to check out our premarket coverage here

Jenny Van Leeuwen Harrington, CEO of Gilman Hill Asset Management, LLC, named Ventas, Inc. (NYSE:VTR) as her final trade.

Lending support to her choice, Scotiabank analyst Nicholas Yulico maintained Ventas at Sector Perform on May 21 and raised the price target from $93 to $95.

SoFi’s Liz Young Thomas picked Pacer US Cash Cows 100 ETF (NASDAQ:COWZ).

Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, named QXO, Inc. (NASDAQ:QXO) as his final trade.

On the earnings front, QXO reported first-quarter losses of 12 cents per share on May 12, missing the analyst consensus estimate of 9 cents per share. The company reported quarterly sales of $1.730 billion which missed the analyst consensus estimate of $1.735 billion.

Price Action Ventas shares fell 0.4% to close at $88.05 on Wednesday. Pacer US Cash Cows 100 ETF slipped 0.02% during the session. Ford shares gained 3.7% to close at $15.88 on Wednesday. QXO shares rose 1.4% to settle at $17.40 on Wednesday. Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

CHICAGO--(BUSINESS WIRE)--Ventas, Inc. (NYSE: VTR) today announced that Chairman and Chief Executive Officer Debra A. Cafaro will receive the Cyrus McCormick Making History Award for Historic Corporate Achievement at the Chicago History Museum’s 32nd Annual Making History Awards this evening.

The Cyrus McCormick Making History Award for Historic Corporate Achievement recognizes business leaders and organizations whose work has made enduring contributions to Chicago’s economic and civic life. Under Cafaro’s leadership, Ventas has grown into one of the world’s leading enterprises at the center of the longevity economy, with ownership of over 1,400 properties and a mission focused on serving a large and growing aging population. The Company is headquartered in Chicago.

“Debra Cafaro exemplifies the leadership and vision that have long defined Chicago’s business community,” said Michael Anderson, Interim President and Chief Executive Officer of the Chicago History Museum. “Through hard work, enduring determination and exceptional strategic leadership, she has built Ventas into one of Chicago’s leading public companies, delivering tremendous value along the way. We are proud to celebrate Debra’s contributions to Chicago and beyond.”

Since 1999, Cafaro has led Ventas through a multi-decade period of strategic growth and value creation – expanding the Company’s market capitalization from $200 million to more than $40 billion. Ventas has grown to a nearly $57 billion enterprise and is the second-largest owner of senior housing in the world, with approximately 900 communities that are home to nearly 100,000 residents and employ over 60,000 workers. Across its properties, the Company is positioned to meet the increasing demand for its high-quality environments that support health, longevity and well-being.

A prominent civic leader in Chicago and beyond, Cafaro is a past Chair of the Economic Club of Chicago and serves on the boards of The PNC Financial Services Group, Inc. (NYSE: PNC), The University of Chicago and the Civic Committee and the Commercial Club of Chicago, in addition to her leadership work for several national organizations. She is also an owner of the NWSL Chicago Stars FC, as well as the MLB Baltimore Orioles and the NHL Pittsburgh Penguins. Cafaro’s biography is available here.

“Chicago has provided a vibrant backdrop for us to grow Ventas over the past three decades,” said Cafaro. “I’m honored to accept this award with deep gratitude to my outstanding colleagues, past and present, whose work is dedicated to supporting people as they age and to strengthening the communities and stakeholders we serve. I’m proud to join fellow honorees whose contributions have left an important mark on Chicago’s history and continue to shape its future.”

The Making History Awards support the Chicago History Museum’s mission to connect people to the city’s history and each other through learning, inspiration and civic engagement.

About Ventas

Ventas, Inc. (NYSE: VTR) is an S&P 500 company enabling exceptional environments that benefit a large and growing aging population. With more than 1,400 properties in North America and the United Kingdom, Ventas occupies an essential role in the longevity economy. The Company’s growth is fueled by its approximately 900 senior housing communities, which provide valuable services to residents and enable them to thrive in supported environments. Ventas aims to deliver outsized performance by leveraging its operational expertise, data-driven insights from its Ventas OITM platform, extensive relationships and strong financial position. The Ventas portfolio also includes outpatient medical buildings, research centers and healthcare facilities. Ventas’s seasoned team of talented professionals shares a commitment to excellence, integrity and a common purpose of helping people live longer, healthier, happier lives.

More News From Ventas, Inc.

NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Biogen Inc.:

Due to the forgoing, The Gross Law Firm is investigating potential securities fraud claims on behalf of certain Biogen Inc. investors. If you incurred a loss on your BIIB investment, please contact us using the link below to discuss your rights.

https://securitiesclasslaw.com/securities/biogen-inc-loss-submission-form-3/?id=187164&from=3 

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected] 
Phone: (646) 453-8903

It has been about a month since the last earnings report for Biogen Inc. (BIIB - Free Report) . Shares have added about 3.8% in that time frame, underperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Biogen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts.

Q1 Earnings & Sales BeatBiogen reported first-quarter 2026 adjusted earnings per share (EPS) of $3.57, which significantly beat the Zacks Consensus Estimate of $2.95. Earnings rose 18% year over year. The adjusted EPS reflected approximately 20 cents per share impact of IPR&D charges, related primarily to Alteogen and Alloy transactions.

Total revenues during the quarter came in at $2.48 billion, up 2% year over year on a reported basis. However, revenues declined 2% on a constant-currency basis. Revenues beat the Zacks Consensus Estimate of $2.25 billion.

Lower sales of key Tecfidera and Spinraza were partially offset by higher revenues from new drugs, 
Skyclarys, Qalsody and Zurzuvae. Improved inventory dynamics also benefited sales of MS drugs like Tysabri and Vumerity in the quarter.

Biogen’s growth products (Skyclarys, Qalsody, Zurzuvae, Vumerity and Spinraza Alzheimer’s revenues form Leqembi collaboration) generated sales of $851 million in the first quarter, rising 12% year over year.

Product sales in the quarter were $1.75 billion, down 3% year over year on a constant currency basis.

Revenues from anti-CD20 therapeutic programs rose 11% to $419 million.

Contract manufacturing and royalty revenues declined 20% year over year to $247.0 million. Alzheimer’s collaboration revenues were $60 million, up 80% year over year.

Alzheimer’s collaboration revenues include Biogen’s 50% share of net product revenues and cost of sales (including royalties) from Leqembi. Eisai recorded nearly $168 million in global revenues from Leqembi sales in the first quarter, up 74% year over year and 25% sequentially, driven by demand growth globally. The drug’s U.S. sales rose 10.3% quarter over quarter to $86 million.

Multiple Sclerosis RevenuesMS revenues totaled $958 million, down 3% on a constant-currency basis, due to generic competition for Tecfidera globally and Tysabri in Europe and rising competitive pressure in the MS market.

Tecfidera sales declined 47% to around $109.5 million due to generic erosion globally, particularly in Europe. The drug’s sales also missed the Zacks Consensus Estimate of $111 million.

Vumerity recorded $179 million in sales, up around 29% year over year, driven by strong demand and improved inventory dynamics in the United States. This metric beat the Zacks Consensus Estimate of $164 million.

Tysabri sales rose 15.7% year over year to $441.5 million as the impact of biosimilar competition in Europe and a decrease in U.S. demand were offset by favorable adjustments to discounts and allowances and the favorable impact of inventory timing. The drug’s sales beat the Zacks Consensus Estimate of $359 million.

Combined interferon revenues (Avonex and Plegridy) were almost flat year over year at about $227.5 million.

In 2026, Biogen expects revenues for MS products, excluding Vumerity, to decline by a mid-teen percentage versus 2025.

Rare Disease DrugsSales of Spinraza declined around 12% to $374 million. The figure missed the Zacks Consensus Estimate of $379 million

Spinraza’s U.S. sales declined 8% year over year to $142.2 million due to lower demand and unfavorable inventory dynamics. In the rest of the world, Spinraza sales declined 14% to $231.8 million due to unfavorable timing of shipments.

Skyclarys generated sales of $150.7 million, up 21.6% year over year, driven by continued demand growth. In the United States, revenues of $71.8 million rose 4% year over year. However, on a sequential basis, Skyclarys’ U.S. sales declined 19.2% due to unfavorable inventory dynamics, which offset the positive impact of moderate demand growth. In ex-U.S. markets, sales rose 44% to $78.9 million, driven by strong adoption trends.

Qalsody added sales of $32.5 million, up more than 100% year over year, driven by demand growth.

In 2026, Biogen expects Rare Disease revenues to grow due to the continued launch of Skyclarys in the EU and other ex-U.S. markets and the continued launch of Qalsody in Europe. Biogen expects global Spinraza revenues to be relatively flat in 2026.

Other ProductsNew drug Zurzuvae (for postpartum depression) recorded sales of nearly $55.4 million in the quarter, down 16% on a sequential basis as demand growth was partially offset by inventory dynamics.

Biosimilar revenues declined 7% year over year to $182 million during the quarter.

Costs DeclineAdjusted research and development (R&D) expenses rose 13% year over year to $480 million due to increased costs behind the company’s late-stage candidates like litifilimab and felzartamab.

Adjusted selling, general and administrative (SG&A) expenses rose 5% to $600 million due to higher costs to support the new product launches.

In the quarter, the collaboration profit-sharing was a net expense of around $74 million, which included nearly $57 million of net profit-sharing expenses related to Biogen’s biosimilar collaboration with Samsung Bioepis and around $17 million of net profit-sharing expenses linked to Biogen’s collaboration with Supernus Pharmaceuticals for marketing Zurzuvae in the United States.

Maintains 2026 GuidanceBiogen maintained its revenue guidance for the year while lowering its earnings guidance to include IPR&D charges related to M&A activities.

Total revenues are expected to decline by a mid-single-digit percentage in constant currency terms in 2026 from the 2025 level. A decline in MS revenues (excluding Vumerity) is expected to be partially offset by higher revenues from growth products.

Adjusted EPS guidance was lowered from a range of $15.25 to $16.25 to $14.25 to $15.25 to include an IPR&D charge of $1.00 per share. The charge comprised approximately 20 cents recorded in the first quarter and approximately 80 cents expected to be recorded in the second quarter (mainly for the TJ Bio transaction for felzartamab rights in China) but does not include any costs related to the Apellis transaction.

Biogen expects Apellis to be accretive to earnings in 2027 and the acquisition to boost Biogen’s adjusted EPS growth rate over the remainder of the decade.

The gross margin in 2026 is expected to be similar to the 2025 levels. Combined adjusted R&D and SG&A costs are also expected to be similar to 2025 levels.

In the second quarter, Biogen expects core operating expenses to be roughly consistent with the first quarter.

How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a downward trend in estimates revision.

The consensus estimate has shifted -20.37% due to these changes.

VGM ScoresAt this time, Biogen has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. However, the stock has a grade of B on the value side, putting it in the second quintile for this investment strategy.

Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Biogen has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Biogen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On May 14, 2026, Biogen issued a press release announcing “topline results from the Phase 2 CELIA study evaluating diranersen (BIIB080), an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer’s disease.” Although Biogen described the results as “compelling,” the study missed its primary dose-response endpoint.

On this news, Biogen’s stock price fell $13.16 per share, or 6.43%, to close at $191.37 per share on May 14, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lower glucocorticoid doses through Week 48 compared with placebo plus standard of care, supporting reduced long-term steroid exposureReduced flare rates and immune marker improvements: In other findings presented at EULAR 2026, improvements in immunological markers and reduced flare rates were observed, supporting the potential of dapirolizumab pegol to address the complex burden of SLE BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical profile of dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE).

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organs, including skin, joints and kidneys, often requiring long-term treatment to control disease activity.1 Patients with SLE frequently experience flares, transient worsening of disease activity that can lead to permanent organ damage, increased morbidity, and even early mortality.2 Many patients rely on steroid-based therapy to manage flares; however, prolonged steroid use is associated with significant cumulative toxicity, making steroid tapering while maintaining disease control a key goal in SLE management.3,4

“Achieving and maintaining durable disease control while reducing glucocorticoid exposure is one of the central challenges in managing SLE,” said Megan E. B. Clowse, M.D., MPH, Chief of the Division of Rheumatology and Immunology, Duke University, and primary author of the PHOENYCS GO primary results. “The Phase 3 PHOENYCS GO data showed patients receiving dapirolizumab pegol were more likely to maintain disease control while tapering steroids – an important finding given strong evidence that cumulative steroid exposure and uncontrolled disease activity are major drivers of organ damage accrual, morbidity and mortality in SLE.”

Post hoc analyses displayed in one of the posters from the PHOENYCS GO program showed that, in patients with baseline glucocorticoid dose >7.5 mg/day prednisone equivalent, treatment with DZP plus standard of care was associated with a higher proportion of patients achieving control of disease activity while enabling glucocorticoid tapering to ≤7.5 mg/day through Week 48, compared with placebo plus standard of care.5 Importantly, these findings suggest that higher proportions of patients receiving DZP plus standard of care versus placebo plus standard of care achieved sustained glucocorticoid tapering while also achieving BICLA response, achieving SRI-4 response, or remaining free from moderate or severe BILAG-2004 flares through Week 48.5

“At UCB, our mission is to help improve the lives of people living with serious inflammatory diseases by advancing therapies that address unmet needs,” said Donatello Crocetta, Chief Medical Officer and Head of Global Medical Affairs at UCB. “These data showed the potential of dapirolizumab pegol to reduce long-term glucocorticoid use while maintaining disease control, an important goal for people living with SLE and the clinicians who care for them.”

Additional EULAR 2026 presentations highlighted the breadth of data from the PHOENYCS GO program, including:

Improvements in key immunological markers, including reduced anti-dsDNA antibodies and increased complement proteins C3 and C4 in patients with abnormal levels at baseline (Poster POS1364).6Lower rates of moderate or moderate/severe BILAG-2004 flares with DZP plus standard of care versus placebo plus standard of care through Week 48, using alternative definitions of flares to increase measurement sensitivity (Abstract AB1163).7Insights into how symptoms and flares are assessed in SLE, including fatigue as a burdensome patient-reported symptom that can be difficult to capture in clinical trials (Abstracts AB1184 and AB1125).8,9
Together, these findings support the importance of tools that can measure patient experience and help inform more meaningful assessment of disease impact in both clinical practice and research.8,9

“Systemic lupus erythematosus is a biologically complex disease, and these EULAR data further characterize dapirolizumab pegol’s impact across clinical, biological and patient-reported outcomes,” said Diana Gallagher, MD, Head of Immunology, MS and Alzheimer’s Development Units at Biogen. “Delivering this data reflects the strength of the UCB and Biogen collaboration and our shared commitment to advancing evidence that may help address the complex and multifaceted needs of people living with SLE.”

The EULAR data follow the recent publication of the Phase 3 PHOENYCS GO study in The Lancet, reporting clinically meaningful improvements in disease activity with dapirolizumab pegol at Week 48.10 In the Phase 3 PHOENYCS GO study, DZP demonstrated a generally favorable safety profile, with safety findings consistent with previous DZP studies.10,11 Treatment-emergent adverse events were more common with DZP plus standard of care versus placebo plus standard of care, while serious treatment-emergent adverse events were less frequent in the DZP plus standard of care arm, and discontinuations due to treatment-emergent adverse events were low in both groups.10

About Dapirolizumab Pegol
Dapirolizumab pegol is a novel investigational humanized Fc-free polyethylene glycol (PEG)-conjugated antigen-binding (Fab’) fragment.11 Dapirolizumab pegol inhibits CD40L signaling, which has been shown to reduce B-cell activation and autoantibody production, mitigate type 1 interferon (IFN) secretion and attenuate T-cell and antigen-presenting cell (APC) activation.11 Dapirolizumab pegol is presently in Phase 3 clinical development for the treatment of systemic lupus erythematosus (SLE) under a collaboration between UCB and Biogen.12,13

Dapirolizumab pegol is an investigational biologic currently in clinical development. The safety and efficacy have not been established, and it is not approved by any health authority worldwide.

About UCB
UCB, Brussels, Belgium (www.ucb.com), is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €7.7 billion in 2025. UCB is listed on Euronext Brussels (symbol: UCB).

About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, LinkedIn, X, YouTube.

Forward-looking Statements - UCB
This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document.

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of UCB’s information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in laws and/or rules pertaining to tax and duties or the administration of such laws and/or rules, and hiring, retention and compliance of employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’s efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems.

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.

UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

Biogen Safe Harbor
This news release contains forward-looking statements, including, among others, relating to: the potential benefits, safety and efficacy of dapirolizumab pegol (DZP); the potential of dapirolizumab pegol to address the needs of people living with systemic lupus erythematosus (SLE), including the potential to help patients maintain disease control while tapering steroids; the anticipated benefits, risks and potential of Biogen's collaboration arrangements with UCB; the potential of Biogen's commercial business and pipeline programs, including dapirolizumab pegol; potential regulatory discussions, submissions and approvals and the timing thereof; and the risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.

These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, factors relating to: uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; and the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov.

These statements speak only as of the date of this presentation and the discussions during this conference call and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our subsequent reports on Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

Biogen Digital Media Disclosure
From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors.

References:

Pons-Estel GJ, Alarcón GS, Scofield L, et al. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010;39(4):257-68.Thanou A, Jupe E, Purushothaman M, et al. Clinical disease activity and flare in SLE: current concepts and novel biomarkers. J Autoimmun. 2021;119:102615. doi:10.1016/j.jaut.2021.102615.Palmowski A, Pankow A, Terziyska K, et al. Continuing versus tapering low-dose glucocorticoids in patients with rheumatoid arthritis and systemic lupus erythematosus in states of low disease activity or remission: a systematic review and meta-analysis of randomised trials. Semin Arthritis Rheum. 2024;64:152349. doi:10.1016/j.semarthrit.2023.152349.Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–45. doi:10.1136/annrheumdis-2019-215089.Morand EF, Bertsias G, Carter LM, et al. Glucocorticoid-sparing maintenance of disease control in patients with systemic lupus erythematosus: 48-week results from a phase 3 trial of dapirolizumab pegol. Ann Rheum Dis. 2026;85(Suppl 1):POS0730.Dörner T, Pisetsky DS, Fava A, et al. Dapirolizumab pegol treatment and improvement in laboratory markers of disease activity in patients with systemic lupus erythematosus: 48-week results from a phase 3 trial. Ann Rheum Dis. 2026;85(Suppl 1):POS1364.Furie RA, Bertsias G, Carter LM, et al. Dapirolizumab pegol and flare reduction in patients with systemic lupus erythematosus in a 48-week phase 3 trial: an updated post hoc analysis of alternative definitions of flares that reflect clinical practice. Ann Rheum Dis. 2026;85(Suppl 1):AB1163.de la Loge C, Touma Z, Gordon C, et al. Measuring fatigue in systemic lupus erythematosus: measurement properties of the FATIGUE-PRO total score using data from a phase 3 trial of dapirolizumab pegol. Ann Rheum Dis. 2026;85(Suppl 1):AB1184.Mosca M, Anjohrin S, Rawlings A, et al. Physicians’ perspectives on recognition of flares in patients with systemic lupus erythematosus in the clinic: real world insights from the United States and Europe. Ann Rheum Dis. 2026;85(Suppl 1):AB1125.Clowse MEB, Isenberg DA, Merrill JT, et al. Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. Published online May 29, 2026. doi:10.1016/S0140-6736(26)00691-4.Furie RA, Bruce IN, Dörner T, et al. Phase 2 randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate to severe active systemic lupus erythematosus (SLE). Rheumatology (Oxford). 2021;60(11): 5397-407.ClinicalTrials.gov. NCT04294667. https://clinicaltrials.gov/study/NCT04294667. Accessed May 29, 2026.ClinicalTrials.gov. NCT06617325. https://clinicaltrials.gov/study/NCT06617325. Accessed May 29, 2026.

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Biogen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On May 14, 2026, Biogen issued a press release announcing "topline results from the Phase 2 CELIA study evaluating diranersen (BIIB080), an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer's disease."  Although Biogen described the results as "compelling," the study missed its primary dose-response endpoint. 

On this news, Biogen's stock price fell $13.16 per share, or 6.43%, to close at $191.37 per share on May 14, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:

Danielle Peyton

Pomerantz LLP

[email protected] 

646-581-9980 ext. 7980

SOURCE Pomerantz LLP

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or “the Company”) (NASDAQ: BIIB) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Biogen revealed on May 14, 2026, that the topline data from its Phase 2 CELIA study for diranersen failed to meet its primary endpoints. Based on these facts, the Company’s shares fell about 6.4% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260604049144/en/

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or "the Company") (NASDAQ: BIIB) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Biogen revealed on May 14, 2026, that the topline data from its Phase 2 CELIA study for diranersen failed to meet its primary endpoints. Based on these facts, the Company's shares fell about 6.4% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
[email protected]
www.schallfirm.com

SOURCE The Schall Law Firm

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Biogen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On May 14, 2026, Biogen issued a press release announcing “topline results from the Phase 2 CELIA study evaluating diranersen (BIIB080), an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer’s disease.”  Although Biogen described the results as “compelling,” the study missed its primary dose-response endpoint. 

On this news, Biogen’s stock price fell $13.16 per share, or 6.43%, to close at $191.37 per share on May 14, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Biogen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On May 14, 2026, Biogen issued a press release announcing "topline results from the Phase 2 CELIA study evaluating diranersen (BIIB080), an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer's disease."  Although Biogen described the results as "compelling," the study missed its primary dose-response endpoint. 

On this news, Biogen's stock price fell $13.16 per share, or 6.43%, to close at $191.37 per share on May 14, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:

Danielle Peyton

Pomerantz LLP

[email protected]

646-581-9980 ext. 7980

SOURCE Pomerantz LLP

Dividend stocks started the new year on a bullish foot. With growth stocks surging again, however, dividend payers have fallen a bit back out of favor.

If you're an income-minded investor though, nothing's really changed... except for the price of the tickers you may be interested in owning. A bunch of them now cost much less than they did just a few weeks ago, while a small handful of them are now dirt cheap. Here's a look at three of the S&P 500's (^GSPC +0.50%) top dividend names that are now down 34%, 29%, and a hefty 37% from recent highs that you may want to scoop up at a discount while you can.

Progressive It's been a tough 12-month stretch for Progressive's (PGR +0.32%) shareholders. The insurer's stock is down 29% from last May's peak, largely on (legitimate) concerns that a fantastic 2024 would be a tough act to follow. Not only has its competition stepped up, but the rising cost of reimbursements poses a clear threat to its profitability. The company's also posted some disappointing quarterly numbers in the meantime.

Today's Change

(

0.32

%) $

0.65

Current Price

$

202.91

For all the naysaying, though, it's worth highlighting that last year's net income grew more than 30% on revenue growth of 16%, which widened its underwriting profit margin from 11.2% to 12.6%. The company's off to a pretty good start this year as well, with net income up 10% through the first three months of 2026 on premium growth of 6% and a 9% increase in the total number of active policies.

Investors are waiting for problems that just aren't materializing. They'll figure it out sooner or later, and likely sooner.

Between now and then, however, this stock's steep sell-off has inflated its trailing dividend yield up to 6.8%. Just bear in mind that the vast majority of its underlying payout is a once-per-year payment of its profits achieved during the year. It's not exactly consistent, even if it is usually sizable. You won't want to make PGR your first or only dividend holding, particularly if you use these dividend payments to pay your bills.

Gen Digital Gen Digital (GEN +1.59%) may be one of the stock market's best-kept secrets. In fact, there's a good chance you've never even heard of it -- its $12 billion market just doesn't turn many heads.

Nevertheless, with a forward-looking dividend yield of 2.5% and a well-established history of paying something every quarter to shareholders, this stock's 37% pullback from August's high makes for a compelling bullish argument.

Gen Digital is a digital security service provider. It does a lot, but you may know it best by its brands LifeLock and Norton. It also owns Avast and financial websites Moneylion and GoBankingRates, which it also operates. Roughly 500 million people use at least one of its products, most of which generate recurring revenue. It was on pace to turn nearly $5 billion worth of revenue into a per-share profit of $2.55 for the fiscal year that ended in March, up 26% and 15%, respectively.

Image source: Getty Images.

As for why shares have performed so poorly of late despite this pullback, dialing back their forward-looking price-to-earnings ratio to less than 7, it was largely caught up in the same sell-off that upended plenty of artificial intelligence (AI) and cybersecurity stocks; broad economic weakness isn't helping either. Indeed, some investors -- professional and amateur alike -- fear that the rise of AI-powered alternatives will reduce the need for custom-coded security solutions like the ones this company offers.

In reality, though, the rise of AI-powered hacking and digital security threats is increasing the need for proven cybersecurity solutions like LifeLock and Norton. As is the case with Progressive, the market should see this soon enough.

The one arguable downside to Gen Digital is that it hasn't raised its dividend since 2020. The company's not necessarily unwilling to do so; it's just waiting for the right time.

Ares Management Last but not least, add Ares Management (ARES +1.57%) to your list of S&P 500 dividend stocks to buy while it's still down 34% from its early January high. Newcomers will be plugging into a forward-looking yield of 4.6%; its dividend has now been raised for eight years in a row.

That's nowhere near the sort of dividend growth track record held by the market's official Dividend Kings, which have upped their annual payouts for a minimum of 50 years. But it's a solid start for this company that's been committed to a more predictable quarterly payout since 2018. And it's improved by more than a little. Its quarterly per-share payment of $0.28 back in 2018 has since grown to this year's payment of $1.35 per share.

Today's Change

(

1.57

%) $

2.08

Current Price

$

134.90

It's a business built for this sort of consistency, of course. Just as the name suggests, Ares Management is an investment manager, collecting a quarterly fee for the capital it provides to companies, and then oversees. It turned $5.6 billion worth of revenue into nearly $1.1 billion in net income last year, most of which was passed along to shareholders in the form of dividends.

That's down slightly from 2024's comparisons, although the market didn't really start to worry about the matter until this year, when broad economic weakness became a much more serious threat to the private credit industry. Investment bank JPMorgan Chase even went as far as to write down the values of some of its private-credit loans last quarter, while -- as part of an effort to curb the liquidity headache that such heavy redemptions cause -- Ares itself recently imposed a limit on the amount of money its investors could withdraw from their stake in the company; it looks problematic.

The headwind isn't anything the asset manager has faced and survived before, however. And buying on these dips has typically paid off in the long run.

xAI's frontier models will supercharge Gen's AI-native products, Norton Neo and AI Assistants, bringing safe and simple autonomous AI to everyone.

, /PRNewswire/ -- Gen (NASDAQ: GEN), the company behind Norton, Avast, LifeLock and MoneyLion, and xAI today announced a partnership to bring xAI's frontier Grok models into Gen's consumer platforms. xAI and Gen will collaborate to rapidly advance their technologies for the next wave of AI-powered consumer products.

Gen and xAI Partner to Build Trusted AI Assistants for Millions of Consumers Through this collaboration, Gen's AI Foundry will use xAI's unique access to coherent compute, data, and technology to bring Grok frontier intelligence to the next generation of secure and trusted consumer AI products, beginning with Norton Neo AI Browser and Assistant powered by Grok.

"As agentic AI systems grow increasingly capable, safely and effectively delivering intelligence to everyday consumers requires robust trust and security infrastructure," said Howie Xu, Chief AI & Innovation Officer. "Through our co-architect partnership, our xAI-powered consumer products will utilize Grok's frontier models to not only answer questions but also take real-world action in a secure and trusted environment."

From Model Intelligence to Trusted Action
Scaling powerful AI responsibly for widespread consumer use benefits from strong safety infrastructure.

As part of this collaboration:

xAI will provide advanced models optimized for reasoning and real-world tasks. xAI frontier intelligence will power agentic systems operating in Gen's secure environment. Gen's Agent Trust Hub will verify, monitor, and enforce safe agent behavior across the full lifecycle of interaction, governing which tools agents use and how they act at runtime. xAI's models will be integrated across Gen's AI-first experiences, starting with the Norton Neo Browser and Assistant, enabling users to interact with AI agents in a secure, trusted environment. All processing is designed by Gen and Norton with privacy and security by default, supported by enterprise-grade protections, including end-to-end encryption and globally recognized security certifications – putting the consumers in control of its privacy.

About Gen
Gen (NASDAQ: GEN) is a global company dedicated to powering Digital Freedom through its trusted consumer brands including Norton, Avast, LifeLock, MoneyLion and more. The Gen family of consumer brands is rooted in providing financial empowerment and cyber safety for the first digital generations. Today, Gen empowers people to live their digital lives safely, privately and confidently for generations to come. Gen brings award-winning products and services in cybersecurity, online privacy, identity protection and financial wellness to nearly 500 million users in more than 150 countries. Learn more at GenDigital.com.

About Gen AI Foundry
Rooted in Gen's commitment to safety and transparency, the Gen AI Foundry is the engine behind its most recent AI innovations, from AI-powered security experiences to autonomous financial helpers and identity agents. It also serves as the place where core trust infrastructure is developed and operationalized, including the Agent Trust Hub, extending protection across the agent lifecycle from verification to execution. Here, Gen's AI strategy becomes real through visible ventures, prototypes, working products, partnerships and an open ecosystem designed to shape and secure the AI era with and for both people and agents.

About xAI
xAI is building artificial intelligence to accelerate our understanding of the universe. Our mission is to advance human scientific discovery by creating AI that is all-encompassing and as far-reaching as possible. Guided by first-principles reasoning, we tackle ambitious challenges with rapid iteration and a focus on solving real problems. We are a focused team driven by curiosity and the pursuit of unprecedented progress. Follow us on x.ai or @xai.

Media Contacts:
Brittany Posey
Gen
[email protected] 

SOURCE Gen Digital Inc.

Key Takeaways GEN expects Q4 revenues of $1.24B-$1.26B, implying 22.7% year-over-year growth.AI-driven platform, Norton 360 and MoneyLion momentum support monetization growth.Weak consumer sentiment and rising AI and R&D spending may pressure margins. Gen Digital (GEN - Free Report) is scheduled to report fourth-quarter fiscal 2026 results on May 7, after market close.

GEN expects non-GAAP revenues in the band of $1.24-$1.26 billion for the quarter. The Zacks Consensus Estimate for revenues is pegged at $1.24 billion, indicating 22.7% year-over-year growth.

For the fiscal fourth quarter, Gen Digital expects non-GAAP earnings in the range of 64-66 cents per share. The consensus mark for the same is pegged at 65 cents per share, suggesting a year-over-year rise of 10.2%. The estimate has remained unchanged over the past 60 days.

GEN’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 2.9%.

Factors to NoteGen Digital is expected to gain from sustained demand for cybersecurity, identity protection and financial safety solutions due to the rapid rise in cyber threats, particularly AI-enabled scams. The emergence of cyber safety and financial wellness is also a tailwind for Gen Digital in the to-be-reported quarter.

Traction in Gen Digital’s unified AI-driven platform, combining data from security, identity and financial behavior and innovation in higher-tier subscriptions like Norton 360 and strong momentum in MoneyLion, will further reinforce monetization tailwinds in the fourth quarter of fiscal 2026.

Momentum in the quarter is likely to have been supported by the AI-powered Genie Scam Protection feature, Norton Deepfake Detection and Norton Neo. An increase in client bookings, supported by strong retention, international expansion and strategic partnerships, is likely to have aided top-line growth in the fiscal third quarter.

Robust demand for identity theft protection solutions, dark web monitoring, social media monitoring, stolen wallet assistant and ID restoration is expected to have been positive for the quarter under review. However, Gen Digital is also facing some near-term headwinds. Weak consumer sentiment could impact discretionary spending on subscriptions.

GEN’s continuous investment in AI, R&D and infrastructure to stay ahead, pressuring margins. The integration of new businesses like MoneyLion introduces execution risks, especially in aligning customer experience and realizing cross-selling synergies. However, GEN’s efforts to innovate make it a strong long-term investment choice.

Earnings Whispers for GEN StockOur proven model predicts an earnings beat for GEN this earnings season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat, which is the case here.

Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (65 cents per share) and the Zacks Consensus Estimate 65 cents per share), is +0.52%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

Zacks Rank: GEN carries a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Stocks to ConsiderHere are some stocks you may want to consider in the broader Zacks Computer and Technology sector, as our model shows that these have the right combination of elements to post an earnings beat:

NVIDIA (NVDA - Free Report) has an Earnings ESP of +0.24% and carries a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

NVIDIA is slated to report first-quarter 2026 results on May 20. The Zacks Consensus Estimate for NVIDIA’s first-quarter earnings is pegged at $1.77 per share, up by a penny over the past 30 days, indicating a rise of 118.5% from the year-ago quarter’s reported figure.

Cisco Systems (CSCO - Free Report) has an Earnings ESP of +1.92% and carries a Zacks Rank #2 at present.

Cisco Systems is set to report third-quarter fiscal 2026 results on May 13. The Zacks Consensus Estimate for Cisco Systems’ third-quarter 2026 earnings is pegged at $1.04 per share, unchanged over the past 60 days, indicating a rise of 8.33% from the year-ago quarter’s reported figure.

Audioeye (AEYE - Free Report) has an Earnings ESP of +9.62% and carries a Zacks Rank #2 at present.

It is set to report first-quarter fiscal 2026 results on May 12. The Zacks Consensus Estimate for Audioeye’s first-quarter earnings is pegged at 17 cents per share, up by 2 cents over the past 60 days, indicating a rise of 13.3% from the year-ago quarter’s reported figure.

With a built-in VPN that adapts automatically, alongside anti-phishing, anti-fingerprinting and smarter ad-block controls, users get the full power of AI browsing without compromise.

, /PRNewswire/ -- Norton, a global leader in consumer Cyber Safety and part of Gen (NASDAQ: GEN), today released a major update to Norton Neo, its AI-native browser. The upgrade embeds integrated VPN, anti-phishing, and anti-fingerprinting protection into the browsing experience. No extensions, no separate tools, no manual set-ups. Norton Neo ensures that AI is not only embedded into a streamlined browsing experience that unifies search and chat, but that protection is built-in by default.

Norton Neo AI-native browser expands built-in privacy and security. According to the Gen Threat Labs, roughly 83% of attacks blocked in early 2026 were web-based, including phishing and spam ads. Gen is also tackling a newer category: indirect prompt injections that hijack AI features through malicious page content. Norton Neo handles these at the browser layer rather than asking users to bolt on protection.

"People can get a lot done on a browser, but digital threats, including spam and phishing, are rampant. Every AI feature added to a browser is another attack surface, and people shouldn't need to be security experts to feel safe online" said Howie Xu, Chief AI and Innovation Officer at Gen. "With Norton Neo, protection isn't a setting you turn on, it's the foundation. The VPN adapts on its own, phishing is caught before you click, and your AI queries can't be turned against you."

Protection That Adapts as You Browse

Adaptive VPN. Norton Neo's built-in VPN encrypts traffic and lets users control their location without a separate install. This built-in VPN intelligently adapts to sensitive sites, like banking or healthcare, and steps back during everyday browsing. By leveraging VPN for Agents, the industry's first consumer multi-channel agent-native VPN service released by Gen on April 30, Norton Neo is able to intelligently apply protection when it's needed without requiring users to turn it on or off.

Advanced anti-fingerprinting. To further strengthen privacy, Norton Neo now helps prevent websites and trackers from uniquely identifying people through their device and browser characteristics. This reduces persistent tracking and enhances anonymity online. Incognito mode now delivers true anonymity, not just the perception of it.

Safe browsing and phishing defense. The browser proactively detects and blocks phishing and malicious websites before people land on them, helping safeguard against credential theft and deceptive online content. Norton Neo extends the same protection to webmail through Norton's Scam Analyzer engine. In addition, the browser defends against indirect prompt injection attacks, so AI features cannot be manipulated by instructions hidden in web content.

Together, these defense layers formed a built-in intelligent protection, backed by the expertise of the Gen Threat Labs and powered by Norton and its decades of security expertise.

More Control, Less Friction

In addition to core protections, Norton Neo has expanded its ad blocking capabilities to offer more granular control over what is blocked and when, allowing customization based on browsing preferences and regional requirements. Cookie consent has also been streamlined to cut down on banner fatigue without giving up control. These updates are designed to simplify privacy management while maintaining strong protection in the background.

To make the browsing experience seamless, Norton Neo extends across platforms, including Windows, Mac, iOS, and Android, ensuring consistent privacy and protection wherever and however people browse. Norton Neo protects people's data and stores all chats locally by default. Queries within the browser are processed under strict, binding contractual safeguards that prevent any AI providers from retaining data or using it for model training. AI providers do not have access to sensitive identification such as IP address or location.

AI That Does More, on a Foundation You Can Trust

Alongside its privacy and security enhancements, Norton Neo continues to expand its AI-native capabilities to help people get more done, more efficiently.

Norton Neo's chat experience now supports deeper reasoning and more complex tasks. With fewer limitations and a more responsive experience, users can explore ideas, refine outputs, and take action without interruption. Unified search lets users find anything they've browsed or discussed in chat using plain language, instead of exact keywords. Features like vertical tabs, better tab management, and a customizable newsfeed round out the experience. As part of this update, Norton Neo also gives its users early access to a new agentic AI assistant; a private, always-on helper for managing online activities, and a step toward Norton's vision of secure AI assistance for everyone.

Learn more and try Norton Neo at neobrowser.ai

About Norton 
Norton is a leader in Cyber Safety, and part of Gen (NASDAQ: GEN), a global company dedicated to powering Digital Freedom with a family of trusted consumer brands. Norton empowers millions of individuals and families with award-winning protection for their devices, online privacy, and identity. Norton products and services are certified by independent testing organizations including AV-TEST, AV Comparatives, and SE Labs. Norton is a founding member of the Coalition Against Stalkerware. Learn more at https://us.norton.com.

Media Contact:
Brittany Posey
Gen
[email protected]

SOURCE Norton

Company Raises FY27 Guidance for Revenue and EPS

, /PRNewswire/ -- Gen Digital Inc. (NASDAQ: GEN), a global leader dedicated to powering Digital Freedom, released its results for fiscal year 2026 fourth quarter and full year, which ended April 3, 2026.

Gen Crosses $5B in FY26 Revenue with Growth Accelerating to Double-Digits "FY26 was a defining year for Gen, our strongest results in a decade, with revenue crossing $5 billion for the first time," said Vincent Pilette, CEO of Gen. "Our guidance proves that we are even more confident today that cyber safety and financial wellness belong together as we continue to expand and connect the Gen platform. And as the world enters the agentic AI era, Gen's platform is uniquely positioned to be the trust layer for everyone. The momentum is ours, and the road ahead has never looked clearer."

Fiscal Year 2026 Financial Highlights

Fiscal Year 2026 GAAP Results

Revenue of $5,000 million, up 27% Operating income of $2,120 million, up 32% Diluted EPS of $1.57, up 53% Operating cash flow of $1,545 million Fiscal Year 2026 Non-GAAP Results

Bookings of $5,107 million, up 28% Revenue of $5,000 million, up 27% Operating income of $2,543 million, up 11% Diluted EPS of $2.56, up 15% Free cash flow of $1,523 million Q4 Fiscal Year 2026 Financial Highlights

Q4 GAAP Results

Revenue of $1,283 million, up 27% Operating income of $803 million, up 93% Diluted EPS of $0.84, up 269% Operating cash flow of $452 million Q4 Non-GAAP Results

Bookings of $1,364 million, up 27% Revenue of $1,283 million, up 27% Operating income of $641 million, up 9% Diluted EPS of $0.67, up 14% Free cash flow of $449 million "Our fourth quarter capped a record year for Gen, with results exceeding guidance, driven by healthy demand for our Cyber Safety Platform, double-digit revenue growth in Trust-Based Solutions and strong execution across the board," said Natalie Derse, CFO of Gen. "This growth momentum, combined with our extraordinary free cash flow generation, gives us the confidence to raise the bar for FY27. We will continue to execute with discipline and allocate capital prioritizing high-return investments to extend our growth and deliver strong returns for our shareholders."

Non-GAAP Q1 Fiscal Year 2027 Guidance

Q1 FY27 Revenue expected to be in the range of $1,300 million to $1,325 million Q1 FY27 EPS expected to be in the range of $0.68 to $0.70 Non-GAAP Fiscal Year 2027 Guidance

FY27 Revenue expected to be in the range of $5,325 million to $5,425 million FY27 EPS expected to be in the range of $2.85 to $2.95 Quarterly Cash Dividend
Gen's Board of Directors has approved a regular quarterly cash dividend of $0.125 per common share to be paid on June 10, 2026, to all shareholders of record as of the close of business on May 18, 2026.

Q4 Fiscal Year 2026 Earnings Call
May 7, 2026
2 p.m. PT / 5 p.m. ET

Webcast & Dial-in instructions at Investor.GenDigital.com. A replay will be posted following the call. For additional details regarding Gen's results and outlook, please see the Financials section of the Investor Relations website at Investor.GenDigital.com.

About Gen
Gen (NASDAQ: GEN) is a global company dedicated to powering Digital Freedom through its trusted consumer brands including Norton, Avast, LifeLock, MoneyLion and more. The Gen family of consumer brands is rooted in providing financial empowerment and cyber safety for the first digital generations. Today, Gen empowers people to live their digital lives safely, privately and confidently for generations to come. Gen brings award-winning products and services in cybersecurity, online privacy, identity protection and financial wellness to nearly 500 million users in more than 150 countries. Learn more at GenDigital.com.

Forward-Looking Statements
This press release contains statements which may be considered forward-looking within the meaning of the U.S. federal securities laws. In some cases, you can identify these forward-looking statements by the use of terms such as "expect," "will," "continue," or similar expressions, and variations or negatives of these words, but the absence of these words does not mean that a statement is not forward-looking. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, but not limited to, the quotes under "Fiscal Year 2026 Financial Highlights" and "Q4 Fiscal Year 2026 Financial Highlights" including expectations relating to achievement of long-term objectives, and the statements under "Non-GAAP Q1 Fiscal Year 2027 Guidance" and "Non-GAAP Fiscal Year 2027 Guidance" including expectations relating to Q1 Fiscal Year 2027 and Fiscal Year 2027 non-GAAP revenue and non-GAAP EPS, and any statements of assumptions underlying any of the foregoing. These statements are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from results expressed or implied in this press release. Such risk factors include, but are not limited to, those related to: the consummation of or anticipated impacts of acquisitions (including our ability to achieve synergies and associated cost savings from any such acquisitions); divestitures, restructurings, stock repurchases, financings, debt repayments and investment activities; the outcome or impact of pending litigation, claims or disputes; difficulties in executing the operating model for the consumer Cyber Safety business; lower than anticipated returns from our investments in direct customer acquisition; difficulties in retaining our existing customers and converting existing non-paying customers to paying customers; difficulties and delays in reducing run rate expenses and monetizing underutilized assets; the successful development of new products and upgrades and the degree to which these new products and upgrades gain market acceptance; our ability to maintain our customer and partner relationships; the anticipated growth of certain market segments; fluctuations and volatility in our stock price; our ability to successfully execute strategic plans; the vulnerability of our solutions, systems, websites and data to intentional disruption by third parties; changes to existing accounting pronouncements or taxation rules or practices; and general business and macroeconomic changes in the U.S. and worldwide, including economic recessions, the impact of inflation, fluctuations in foreign currency exchange rates, changes in interest rates or tax rates, and ongoing and new geopolitical conflicts, and other global macroeconomic factors on our operations and financial performance. Additional information concerning these and other risk factors is contained in the Risk Factors sections of our most recent reports on Form 10-K and Form 10-Q. We encourage you to read those sections carefully. There may also be other factors that have not been anticipated or are not described in our periodic filings, generally because we did not believe them to be significant at the time, which could cause actual results to differ materially from our projections and expectations. All forward-looking statements should be evaluated with the understanding of their inherent uncertainty. We assume no obligation, and do not intend, to update these forward-looking statements as a result of future events or developments.

Use of Non-GAAP Financial Information
We use non-GAAP measures of operating margin, operating income, net income and earnings per share, which are adjusted from results based on GAAP and exclude certain expenses, gains and losses. We also provide the non-GAAP metrics of revenues, and constant currency revenues. These non-GAAP financial measures are provided to enhance the user's understanding of our past financial performance and our prospects for the future. Our management team uses these non-GAAP financial measures in assessing Gen's performance, as well as in planning and forecasting future periods. These non-GAAP financial measures are not computed according to GAAP and the methods we use to compute them may differ from the methods used by other companies. Non-GAAP financial measures are supplemental, should not be considered a substitute for financial information presented in accordance with GAAP and should be read only in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP. Readers are encouraged to review the reconciliation of our non-GAAP financial measures to the comparable GAAP results, which is attached to our quarterly earnings release, and which can be found, along with other financial information including the Earnings Presentation, on the investor relations page of our website at Investor.GenDigital.com. No reconciliation of the forecasted range for non-GAAP revenues and EPS guidance is included in this release because most non-GAAP adjustments pertain to events that have not yet occurred. It would be unreasonably burdensome to forecast, therefore we are unable to provide an accurate estimate.

GEN DIGITAL INC.

Condensed Consolidated Balance Sheets

(Unaudited, in millions)

April 3, 2026

March 28, 2025

ASSETS

Current assets:

Cash, cash equivalents and restricted cash

$               411

$            1,006

Accounts receivable, net

361

171

Other current assets

295

245

Assets held for sale

14

22

       Total current assets

1,081

1,444

Property and equipment, net

71

60

Intangible assets, net

2,096

2,267

Goodwill

10,996

10,237

Deferred income tax assets

1,153

1,218

Other long-term assets

192

269

     Total assets

$         15,589

$         15,495

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable

$                96

$                94

Accrued compensation and benefits

115

105

Current portion of long-term debt

181

291

Contract liabilities

1,904

1,846

Other current liabilities

414

515

       Total current liabilities

2,710

2,851

Long-term debt

8,015

7,968

Long-term contract liabilities

73

77

Deferred income tax liabilities

198

222

Long-term income taxes payable

1,588

1,420

Other long-term liabilities

394

688

            Total liabilities

12,978

13,226

            Total stockholders' equity (deficit)

2,611

2,269

     Total liabilities and stockholders' equity

$         15,589

$         15,495

GEN DIGITAL INC.

Condensed Consolidated Statements of Operations

(Unaudited, in millions, except per share amounts)

Three Months Ended

Year Ended

April 3, 2026

March 28, 2025

April 3, 2026

March 28, 2025

Net revenues

$          1,283

$          1,010

$          5,000

$          3,935

Cost of revenues

276

199

1,077

776

Gross profit

1,007

811

3,923

3,159

Operating expenses:

Sales and marketing

327

196

1,228

745

Research and development

104

81

409

329

General and administrative

(291)

67

(87)

291

Amortization of intangible assets

54

44

218

174

Restructuring and other costs

10

3

35

7

Impairment of intangible assets

—

3

—

3

       Total operating expenses

204

394

1,803

1,549

Operating income (loss)

803

417

2,120

1,610

Interest expense

(130)

(135)

(569)

(578)

Other income (expense), net

(4)

5

(40)

(3)

Income (loss) before income taxes

669

287

1,511

1,029

Income tax expense (benefit)

157

145

538

386

Net income (loss)

$             512

$             142

$             973

$             643

Net income (loss) per share - basic

$            0.85

$            0.23

$            1.59

$            1.04

Net income (loss) per share - diluted

$            0.84

$            0.23

$            1.57

$            1.03

Weighted-average shares outstanding:

Basic

602

616

612

617

Diluted

609

624

619

624

GEN DIGITAL INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited, in millions)

Three Months Ended

Year Ended

April 3, 2026

March 28, 2025

April 3, 2026

March 28, 2025

OPERATING ACTIVITIES:

Net income (loss)

$            512

$            142

$            973

$            643

Adjustments:

Amortization and depreciation

119

104

493

419

Impairments and write-offs of current and long-lived assets

—

5

—

7

Stock-based compensation expense

62

36

237

133

Loss on sale of Instacash Advances

59

—

205

—

Deferred income taxes

92

18

92

(32)

Loss on extinguishment of debt

9

—

9

—

Gain on sale of nonfinancial assets

—

—

(15)

—

Non-cash operating lease expense

5

5

18

16

Change in fair value and impairment of non-marketable equity
investments

—

—

79

30

Foreign currency remeasurement loss (gain)

(32)

12

54

(2)

Legal contract dispute cost (1)

—

24

—

66

Other

12

3

47

13

Changes in operating assets and liabilities, net of
acquisitions:

Accounts receivable, net

7

(19)

(32)

(53)

Accounts payable

4

(9)

(48)

26

Accrued compensation and benefits

(3)

11

8

27

Contract liabilities

75

63

74

36

Income taxes payable

17

56

(96)

(80)

Instacash Advances held for sale, net

(57)

—

(205)

—

Other assets

(56)

11

16

86

Other liabilities

(373)

11

(364)

(114)

       Net cash provided by (used in) operating activities

452

473

1,545

1,221

INVESTING ACTIVITIES:

Purchases of property and equipment

(3)

(3)

(22)

(15)

Purchase of non-marketable equity investments

—

—

—

(4)

Payments for acquisitions, net of cash acquired

(156)

(84)

(1,032)

(84)

Payments for originations of notes receivable

(83)

—

(283)

—

Proceeds from principal repayments of notes receivable

80

—

253

—

Proceeds from the maturities and sales of short-term
investments

—

—

13

—

Proceeds from the sale of properties

—

—

21

—

Proceeds from sale of nonfinancial assets

—

—

40

—

Other

—

4

(1)

3

Net cash provided by (used in) investing activities

(162)

(83)

(1,011)

(100)

FINANCING ACTIVITIES:

Repayments of debt

(2,960)

(1,164)

(3,620)

(1,311)

Proceeds from issuance of debt, net of issuance costs (2)

2,734

941

3,475

941

Net proceeds from sales of common stock under employee
stock incentive plans

6

5

13

11

Tax payments related to vesting of stock units

(3)

(1)

(55)

(26)

Dividends and dividend equivalents paid

(76)

(77)

(312)

(313)

Repurchases of common stock

(200)

—

(634)

(272)

Net cash provided by (used in) financing activities

(499)

(296)

(1,133)

(970)

Effect of exchange rate fluctuations on cash, cash equivalents           
and restricted cash

1

29

4

9

Change in cash, cash equivalents and restricted cash

(208)

123

(595)

160

Beginning cash, cash equivalents and restricted cash

619

883

1,006

846

Ending cash, cash equivalents and restricted cash

$            411

$          1,006

$            411

$          1,006

______________________

(1)

During fiscal 2025, in connection with a legal settlement terminating our agreement with an Avast e-commerce partner that acted as payment processor and merchant of record for a subset of customers, we released our claims to $66 million of outstanding accounts receivable (net of fees payable) in exchange for the transfer of the related customer information to us. The $66 million was charged off as general and administrative expense and is reflected as a non-cash item within the change in accounts receivable in operating activities for fiscal 2025. No comparable activity occurred in fiscal 2026 or fiscal 2024.

(2)

Issuance costs paid for issuance of debt for the three months ended April 3, 2026 and March 28, 2025 was $7 million and $9 million, respectively, and for the fiscal year ended 2026 and 2025 was $16 million and $9 million, respectively.

GEN DIGITAL INC.

Reconciliation of Selected GAAP Measures to Non-GAAP Measures (1) (2)

(Unaudited, in millions, except per share amounts)

Three Months Ended

Year Ended

April 3, 2026

March 28, 2025

April 3, 2026

March 28, 2025

Operating income (loss)

$           803

$           417

$         2,120

$         1,610

Stock-based compensation

62

37

235

134

Amortization of intangible assets

115

100

477

401

Impairment of intangible assets

—

3

—

3

Restructuring and other costs

10

3

35

7

Acquisition and integration costs

3

1

12

11

Litigation costs

(353)

4

(336)

65

Legal contract dispute cost

—

24

—

66

Other

1

1

—

1

Operating income (loss) (Non-GAAP)

$           641

$           590

$         2,543

$         2,298

Operating margin

62.6 %

41.3 %

42.4 %

40.9 %

Operating margin (Non-GAAP)

50.0 %

58.4 %

50.9 %

58.4 %

Net income (loss)

$           512

$           142

$            973

$            643

Adjustments to net income (loss):

Stock-based compensation

62

37

235

134

Amortization of intangible assets

115

100

477

401

Impairment of intangible assets

—

3

—

3

Restructuring and other costs

10

3

35

7

Acquisition and integration costs

3

1

12

11

Litigation costs

(353)

4

(336)

65

Legal contract dispute cost

—

24

—

66

Other

—

4

—

6

Non-cash interest expense

8

6

28

26

Loss (gain) on extinguishment of debt

9

—

9

—

Loss (gain) on equity investments

—

—

79

30

Loss (gain) on sale of properties

—

—

(15)

—

Total adjustments to GAAP income (loss) before income taxes

(146)

182

524

749

Adjustment to GAAP provision for income taxes

42

42

90

(5)

Total adjustment to income (loss), net of taxes

(104)

224

614

744

Net income (loss) (Non-GAAP)

$           408

$           366

$         1,587

$         1,387

Diluted net income (loss) per share

$          0.84

$          0.23

$           1.57

$           1.03

Adjustments to diluted net income (loss) per share:

Stock-based compensation

0.10

0.06

0.38

0.21

Amortization of intangible assets

0.19

0.16

0.77

0.64

Impairment of intangible assets

—

0.00

—

0.00

Restructuring and other costs

0.02

0.00

0.06

0.01

Acquisition and integration costs

0.00

0.00

0.02

0.02

Litigation costs

(0.58)

0.01

(0.54)

0.10

Legal contract dispute cost

—

0.04

—

0.11

Other

—

0.01

—

0.01

Non-cash interest expense

0.01

0.01

0.05

0.04

Loss (gain) on extinguishment of debt

0.01

—

0.01

—

Loss (gain) on equity investments

—

—

0.13

0.05

Loss (gain) on sale of properties

—

—

(0.02)

—

Total adjustments to GAAP income (loss) before income taxes

(0.24)

0.29

0.85

1.20

Adjustment to GAAP provision for income taxes

0.07

0.07

0.15

(0.01)

Total adjustment to income (loss), net of taxes

(0.17)

0.36

0.99

1.19

Diluted net income (loss) per share (Non-GAAP)

$          0.67

$          0.59

$          2.56

$          2.22

Diluted weighted-average shares outstanding

609

624

619

624

Diluted weighted-average shares outstanding (Non-GAAP)

609

624

619

624

GEN DIGITAL INC.

Reconciliation of Selected GAAP Measures to Non-GAAP Measures (1) (2)

(Unaudited, in millions, except per share amounts)

Three Months Ended

Year Ended

April 3, 2026

March 28, 2025

April 3, 2026

March 28, 2025

Net cash provided by (used in) operating activities

$            452

$            473

$          1,545

$          1,221

Adjustments to net cash provided by (used in) operating activities:

Purchases of property and equipment

(3)

(3)

(22)

(15)

Free cash flow (Non-GAAP)

$            449

$            470

$          1,523

$          1,206

______________________

(1)

This presentation includes non-GAAP measures. Non-GAAP financial measures are supplemental and should not be considered a substitute for financial information presented in accordance with GAAP. For a detailed explanation of these non-GAAP measures, see Appendix A.

(2)

Amounts may not add due to rounding.

GEN DIGITAL INC.

Performance Metrics

(Unaudited, in millions)

Performance Metrics

Three Months Ended

Year Ended

April 3, 2026

January 2, 2026

March 28, 2025

April 3, 2026

March 28, 2025

Cyber Safety Platform                                                  

$             837

$             819

$            808

$          3,339

$         3,176

Trust-Based Solutions

446

421

202

1,661

759

Total net revenues

$          1,283

$          1,240

$         1,010

$          5,000

$         3,935

Direct revenues

$          1,048

$          1,025

$            878

$          4,137

$         3,463

Partner revenues

235

215

132

863

472

Total net revenues

$          1,283

$          1,240

$         1,010

$          5,000

$         3,935

Total bookings

$          1,364

$          1,319

$         1,076

$          5,107

$         3,988

As of

April 3, 2026

March 28, 2025

Total paid customers

79

68

GEN DIGITAL INC.
Appendix A
Explanation of Non-GAAP Measures and Other Items

Objective of non-GAAP measures: We believe our presentation of non-GAAP financial measures, when taken together with corresponding GAAP financial measures, provides meaningful supplemental information regarding the Company's operating performance for the reasons discussed below. Our management team uses these non-GAAP financial measures in assessing our performance, as well as in planning and forecasting future periods. Due to the importance of these measures in managing the business, we use non-GAAP measures in the evaluation of management's compensation. These non-GAAP financial measures are not computed according to GAAP and the methods we use to compute them may differ from the methods used by other companies. Non-GAAP financial measures are supplemental and should not be considered a substitute for financial information presented in accordance with GAAP and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP.

Stock-based compensation: This consists of expenses for employee restricted stock units, performance-based awards, stock options and our employee stock purchase plan, determined in accordance with GAAP. We evaluate our performance both with and without these measures because stock-based compensation is a non-cash expense and can vary significantly over time based on the timing, size, nature and design of the awards granted, and is influenced in part by certain factors that are generally beyond our control, such as the volatility of the market value of our common stock. In addition, for comparability purposes, we believe it is useful to provide a non-GAAP financial measure that excludes stock-based compensation to facilitate the comparison of our results to those of other companies in our industry.

Amortization of intangible assets: Amortization of intangible assets consists of amortization of acquisition-related intangibles assets such as developed technology, customer relationships and trade names acquired in connection with business combinations. We record charges relating to the amortization of these intangibles within both cost of revenues and operating expenses in our GAAP financial statements. Under purchase accounting, we are required to allocate a portion of the purchase price to intangible assets acquired and amortize this amount over the estimated useful lives of the acquired intangible assets. However, the purchase price allocated to these assets is not necessarily reflective of the cost we would incur to internally develop the intangible asset. Further, amortization charges for our acquired intangible assets are inconsistent in size and are significantly impacted by the timing and valuation of our acquisitions. We eliminate these charges from our non-GAAP operating results to facilitate an evaluation of our current operating performance and provide better comparability to our past operating performance.

Restructuring and other costs: Restructuring charges are costs associated with a formal restructuring plan and are primarily related to employee severance and benefit arrangements, contract termination costs, and assets write-offs, as well as other exit and disposal costs. Included in other exit and disposal costs are costs to exit and consolidate facilities in connection with restructuring events. We exclude restructuring and other costs from our non-GAAP results as we believe that these costs are incremental to core activities that arise in the ordinary course of our business and do not reflect our current operating performance, and that excluding these charges facilitates a more meaningful evaluation of our current operating performance and comparisons to our past operating performance.

Acquisition-related and integration costs: These represent the transaction and business integration costs related to significant acquisitions that are charged to operating expense in our GAAP financial statements. These costs include incremental expenses incurred to affect these business combinations such as advisory, legal, accounting, valuation, and other professional or consulting fees. We exclude these costs from our non-GAAP results as they have no direct correlation to the operation of our business, and because we believe that the non-GAAP financial measures excluding these costs provide meaningful supplemental information regarding the spending trends of our business. In addition, these costs vary, depending on the size and complexity of the acquisitions, and are not indicative of costs of future acquisitions.

Litigation costs: We may periodically incur charges or benefits related to litigation settlements, legal contingency accruals and third-party legal costs related to certain legal matters. We exclude these charges and benefits when associated with a significant matter because we do not believe they are reflective of ongoing business and operating results. 

Legal contract dispute cost: During fiscal 2025, we incurred charges in connection with an e-commerce partner settlement. In order to resolve all open disputes with the partner, we entered into a legal settlement agreement which included our release of claims to valid outstanding accounts receivable totaling $66 million, which were charged off as G&A expense in fiscal 2025. We exclude these charges and benefits when associated with a significant matter because we do not believe they are normal, recurring, or reflective of ongoing business and operating results.

Non-cash interest expense and amortization of debt issuance costs: In accordance with GAAP, we separately account for the value of the conversion feature on our convertible notes as a debt discount that reflects our assumed non-convertible debt borrowing rates. We amortize the discount and debt issuance costs over the term of the related debt. We exclude the difference between the imputed interest expense, which includes the amortization of the conversion feature and of the issuance costs, and the coupon interest payments. We extinguished our remaining convertible debt on August 15, 2022. During fiscal 2023, we also started amortizing the debt issuance costs associated with our senior credit facilities, which were secured upon close of the acquisition of Avast. We believe that excluding these costs provides meaningful supplemental information regarding the cash cost of our debt instruments and enhance investors' ability to view the Company's results from management's perspective.

Gain (loss) on extinguishment of debt: We record gains or losses on extinguishment of debt. Gains or losses represent the difference between the fair value of the exchange consideration and the carrying value of the liability component of the debt at the date of extinguishment. We exclude the gain or loss on debt extinguishment in our non-GAAP results because they are not reflective of our ongoing business.

Change in fair value and impairment of non-marketable equity investments: We record gains or losses, unrealized and realized, on equity investments in privately-held companies. We exclude the net gains or losses because we do not believe they are reflective of our ongoing business.

Gain (loss) on sale of properties and nonfinancial assets: We periodically recognize gains or losses from the disposition of land, buildings and nonfinancial assets. We exclude such gains or losses because they are not reflective of our ongoing business and operating results.

Income tax effects and adjustments: We use a non-GAAP tax rate that excludes (1) the discrete impacts of changes in tax legislation, (2) most other significant discrete items, (3) unrealized gains or losses from remeasurement of foreign currency denominated deferred tax items and uncertain tax benefits, and (4) the income tax effects of the non-GAAP adjustment to our operating results described above. We believe making these adjustments facilitates a better evaluation of our current operating performance and comparisons to past operating results. Our tax rate is subject to change for a variety of reasons, such as significant changes in the geographic earnings mix due to acquisition and divestiture activities or fundamental tax law changes in major jurisdictions where we operate.

Diluted GAAP and non-GAAP weighted-average shares outstanding: Diluted GAAP and non-GAAP weighted-average shares outstanding are generally the same, except in periods when there is a GAAP loss from continuing operations. In accordance with GAAP, we do not present dilution for GAAP in periods in which there is a loss from continuing operations. However, if there is non-GAAP net income, we present dilution for non-GAAP weighted-average shares outstanding in an amount equal to the dilution that would have been presented had there been GAAP income from continuing operations for the period.

Bookings: Bookings are defined as customer orders received that are expected to generate net revenues in the future. We present the operational metric of bookings because it reflects customers' demand for our products and services and to assist readers in analyzing our performance in future periods.

Free cash flow: Free cash flow is defined as cash flows from operating activities less purchases of property and equipment. Free cash flow is not a measure of financial condition under GAAP and does not reflect our future contractual commitments and the total increase or decrease of our cash balance for a given period, and thus should not be considered as an alternative to cash flows from operating activities or as a measure of liquidity.

(Unlevered) Free cash flow: Free cash flow is defined as cash flows from operating activities less purchases of property and equipment. Unlevered free cash flow excludes cash interest expense payments, net of payments received through interest rate swap hedges. Free cash flow is not a measure of financial condition under GAAP and does not reflect our future contractual commitments and the total increase or decrease of our cash balance for a given period, and thus should not be considered as an alternative to cash flows from operating activities or as a measure of liquidity.

Cyber Safety Platform: Includes our security and privacy products, as well as our cyber safety comprehensive suites which deliver technology solutions and superior threat protection to help people navigate the digital world, securely, privately and confidently.

Trust-Based Solutions: Trust-Based Solutions includes our identity, reputation, and financial wellness products, which provide innovative solutions and insights that empower consumers to grow and manage their identity, reputation and finances confidently.

Direct revenue: Direct revenue reflects subscriptions sold directly through e-commerce or mobile channels, and revenue generated from financial transactions directly made through Gen properties or marketplaces.

Partner revenue: Partner revenue reflects partner-sourced and channel revenue via retailers, employee benefits, telcos, publishers, and strategic partnerships, including revenue generated from product usage or products sold through our financial marketplace.

Paid customers: We define paid customers as active users of our products and solutions, including subscribers with an active paid subscription to our products at the end of the reported period. Paid customers also includes product users with a unique account and at least one revenue-generating transaction in the relevant active period of each respective product category, whether through our first-party personal finance products, transacting through our financial marketplaces, or generating revenue through product usage. We exclude users on free trials and those who have not actively transacted in the relevant period of each respective product category. In order to properly reflect Gen's customer cohorts that contribute to revenue given the dynamic nature of consumers and our product portfolio, our methodology is subject to change from time to time. The methodologies used to measure these metrics require judgment and we regularly review our metrics to improve their accuracy. However, our ability to recalculate our historical metrics may be impacted by data limitations or other factors that require us to apply different methodologies for such adjustments. We generally do not intend to update previously disclosed metrics for any such inaccuracies or adjustments that are deemed not material.

CONTACTS

Investor Contact

Ben Lu

Media Contact

Audra Proctor

Gen

Gen

[email protected]   

[email protected]

SOURCE Gen Digital Inc.

Gen Digital Inc. (GEN) Q4 2026 Earnings Call Transcript

The most comprehensive free consumer cybersecurity solution available — then add only what you need and skip what you don't.

, /PRNewswire/ -- You already know what you need for your digital life. You've done the research, read the threads, tuned the settings. The last thing you want is a security suite that assumes you haven't.

Avast One

Avast One product experience Today, Avast, a leader in digital security and privacy and part of Gen (NASDAQ: GEN), is launching a reimagined Avast One that puts you in the driver's seat. Avast One comes with powerful free protection right from the start. Then, if your situation changes, add only the protections you want, directly inside the same app. Your choices. Your tools. Nothing else.

The free tier of Avast One provides comprehensive protection, not a stripped-down teaser designed to pressure an upgrade. You get free antivirus and real-time threat protection, AI-powered scam detection, a no-log VPN, data breach monitoring, AI Agent Protection, and device cleanup – all fully functional.

"People know what they value and how they want to protect their digital lives," said Travis Witteveen, Head of Products and Portfolios at Gen. "Avast One has been designed to give you greater choice and control making it easy to personalize protection, manage features, and only pay for what you truly need."

What the free tier covers:

Scam Protection: Built-in AI-powered scam protection that blocks phishing links, fraudulent shopping sites, and banking scams in real-time — while you're browsing, not after credentials are stolen. Includes the Avast AI Assistant for scam and product guidance. Antivirus and Real-Time Threat Protection: Detects and blocks malware, viruses, and malicious downloads before they execute. Intercepts dangerous sites before pages load. Stops ransomware before files are encrypted. You know the drill — this one just does it properly. AI Agent Protection: AI tools acting on your behalf can be hijacked. Avast One vets plugins before they run, blocks malicious instructions injected into AI workflows, and checks AI-generated files before they reach your system. No-Log VPN*: Enhanced, no-log VPN experience with improved privacy protections, protocol options, and a wider selection of server locations. Data Breach Monitoring**: Scans breach databases for your personal information, shows exactly where it was exposed, and walks you through containing the damage. Device Cleanup: Removes junk files, duplicate photos, redundant browser data, and old contacts to restore device performance. Add more when you want it:

Avast One is built to flex with how you actually live online. When something changes — a new threat you care about, a device running slower than it should, scam calls that keep getting through — you can unlock more protection without switching apps, re-entering payment details, or rebuilding your setup from scratch.

Want more muscle against scam calls and phishing emails? Unlock Avast Premium Security with Scam Protection Pro. Want automated, intelligent cleanup that keeps your laptop running like it should? Unlock Avast Cleanup Premium. When you need it, add it. You choose the pieces. You decide when.

The specifics:

The new Avast One is available now on Windows, macOS, Android, and iOS. All paid plans cover desktop and mobile under a single subscription. Running the previous Avast One? The new experience is ready when you are. Install it and everything ports overs. No rush – your existing product remains fully supported.

Download the free version at avast.com/avast-one. No credit card required.

*Avast SecureLine VPN is a 60-day trial requiring a payment method at sign-up. Billed at the end of the trial period unless cancelled first.

**BreachGuard is currently only available on desktop.

About Avast
Avast is a leader in digital security and privacy, and part of Gen (NASDAQ: GEN), a global company dedicated to powering Digital Freedom with a family of trusted consumer brands. Avast protects hundreds of millions of users from online threats, for Mobile, PC or Mac, and is top-ranked and certified by VB100, AV-Comparatives, AV-Test, SE Labs and others. Avast is a member of the Coalition Against Stalkerware, No More Ransom and Internet Watch Foundation. Learn more at Avast.com.

SOURCE Gen Digital Inc.

MoneyLion will give away $500 to two winners every day from May 26 through July 4th, totaling $40,000 in summer financial relief

, /PRNewswire/ -- According to a new MoneyLion in-app survey, summer spending has a way of getting ahead of even the best-laid plans. Nearly half of consumers (47%) say family activities and BBQs are the summer moments they're most likely to overspend on even when budgets are tight, and more than a third (35%) expect weekend trips to cost more than they budgeted. To help ease the financial pressure that comes with the season, MoneyLion is launching its Summer Break Giveaway, awarding $500 to two winners every day from May 26 through July 4 — $40,000 in total.

MoneyLion Launches Summer Break Giveaway to Give Consumers a Much-Needed Financial Breather The Summer Break Giveaway is inspired by the reality that summer is full of moments people don't want to miss, and that the costs add up fast. From mini vacations (the most common splurge at 35%) to last-minute dinner plans (50% of those surveyed always say yes to last-minute invites), the season brings a steady stream of financial decisions. The giveaway offers timely relief, giving people the breathing room to enjoy summer without the financial stress that often follows.

"At a time of year when spending can increase quickly, even for well-intentioned consumers, summer also creates meaningful opportunities for connection and celebration," said Ferha Mirdawi, Head of Marketing for MoneyLion. "The Summer Break Giveaway reflects MoneyLion's commitment to helping consumers navigate seasonal expenses with greater confidence and financial flexibility, so they can enjoy the moments that matter most."

Enter now at moneylion.com/summerbreak and follow MoneyLion on TikTok, X, and Instagram for updates and winner announcements.

The giveaway runs May 26, 2026 at approximately 9:00 AM ET through July 4, 2026 at 11:59:59 PM ET. Two winners will be selected daily, each receiving $500.

No purchase is required. Open to residents of all 50 United States and the District of Columbia. Message and data rates may apply. Subject to complete Official Rules including entry method, prize descriptions and odds of winning at https://www.moneylion.com/learn/personal-finance/basics/moneylion-2026-summer-break-giveaway-official-rules . Void where prohibited. Sponsor: MoneyLion Technologies Inc.

Survey Methodology

MoneyLion surveyed more than 1,000 adults ages 18 and over via the MoneyLion app.

About MoneyLion
MoneyLion is a leading financial technology platform and part of Gen (NASDAQ: GEN), a global company dedicated to powering Digital Freedom with a family of trusted consumer brands. MoneyLion powers the next generation of personalized products, content, and marketplace technology through its top-rated consumer finance super app, premier embedded finance platform for enterprise businesses, and world-class media arm. Consumers gain control of their finances with an innovative suite of products to save, borrow, spend, and invest, seamlessly integrating the best offers and content from MoneyLion and its 1,300+ enterprise partners into one unified experience. Its mission is to give everyone the power to make their best financial decisions. Learn more at www.moneylion.com. 

Media contact: 
Malea Lamb-Hall
Gen
[email protected] 

SOURCE Gen Digital Inc.

SAN FRANCISCO, June 02, 2026 (GLOBE NEWSWIRE) -- Javelin Strategy & Research today released its 2026 Direct-to-Consumer Identity Protection Services Vendor Scorecard, evaluating 14 identity protection service providers. This year’s findings reveal that the market continues to evolve beyond traditional identity theft protection toward scam prevention, cybersecurity integration, and family-focused protections. However, major gaps remain. No providers offer advanced predictive modeling for socially engineered attack mitigation, and just 21% monitor children’s online gaming risks. Few vendors provide robust social media or dark web cleanup services—services which Javelin deems critical for the future of digital risk resiliency.

The IDPS market has become increasingly complex for consumers to navigate as offerings expand into broader digital protection and cybersecurity services. Consumer investment in IDPS subscriptions has softened, creating new pressure for providers to communicate the value of their protections better.

“The strongest providers are moving beyond reactive alerts to deliver more proactive scam prevention, analytical intelligence, and cyber risk protection,” said Tracy Goldberg, Director of Javelin’s Cybersecurity practice and author of the scorecard report.

Gen Digital, provider of Norton 360 with LifeLock Ultimate Plus, was named Best in Class for its leadership in comprehensive monitoring, scam protection, authentication, and customer support. The company also ranked highest in four of the scorecard’s five categories, with standout capabilities addressing social media and online gaming risks.

Equifax, provider of ID Watchdog Premium Family, was named an overall Leader for its strengths in child identity theft protection and cybersecurity risk mitigation. Allstate Identity Protection, provider of Blue Family, was also named an overall Leader, recognized for its strong customer support experience and dedicated onboarding assistance for families implementing child protections.

“Identity theft recovery has become too difficult for consumers to navigate alone,” Goldberg added. “As scams and identity threats become more sophisticated, consumers increasingly need real-time human support from identity protection providers to help them navigate today’s emerging cybersecurity risks.”

Javelin’s biannual 2026 Direct-to-Consumer Identity Protection Services Vendor Scorecard is designed to help financial institutions, financial services providers, and IDPS vendors better understand the rapidly evolving identity protection landscape. This year’s scorecard assessment evaluates 14 direct-to-consumer identity protection providers across 185 criteria and five categories: Detection & Monitoring, User Experience, Prevention, Resolution, and Onboarding & Authentication.

About Javelin Strategy & Research

Javelin Strategy & Research, part of Escalent Group, helps its clients make informed decisions in a digital financial world. It provides strategic insights to financial institutions including banks, credit unions, brokerages and insurers, as well as payments companies, technology providers, fintechs and government agencies. Javelin’s independent insights result from a rigorous research process that assesses consumers, businesses, providers, and the transactions ecosystem. It conducts in-depth primary research studies to pinpoint dynamic risks and opportunities in digital banking, payments, and fraud & security. Learn more at javelinstrategy.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ef8410e9-4811-42a4-81e3-8610cff53953

Javelin's 2026 Direct-to-Consumer Identity Protection Services Vendor Scorecard Results Gen Digital earns Best in Class; Equifax and Allstate Identity Protection named overall Leaders

From AI-powered imposter fraud to reservation hijacking, Norton pinpoints the attacks surging most between now and Labor Day

, /PRNewswire/ -- SPF isn't the only protection you need this summer. Norton, a global leader in consumer Cyber Safety and part of Gen (NASDAQ: GEN), today launched Scam Free Summer to help people spot and stop the scams that spike in in the summer months. The forecast shines light on the moments scammers tend to show up most.

Watch out for these top 10 threats identified by Norton for a Scam Free Summer Norton's 2026 Summer Scam Forecast shares the 10 scam types projected to be most active this summer, grounded in a Norton analysis of millions of scam attacks blocked by Norton in 2024 and 2025 and cross-referenced against emerging threat patterns from spring 2026.

Why is Summer So Hot For Some Scams?

"Scammers follow the calendar," said Leyla Bilge, Global Head of Scam Research for Norton. "People are understandably distracted, spending more on travel and tickets, tapping confirmation links without a second look. Scam Free Summer gives you the playbook to enjoy the season without lining a scammer's pockets."

Gen's threat data shares the top trends:

Imposter scams are when fraudsters pose as family members, government agencies, or known contacts. These jumped 144% last summer compared to the rest of the year. Financial scam attacks in the U.S. were up 55% versus the annual average. Package delivery scams rose 89%. Gambling fraud climbed 88%, driven by summer sports events. What's new in 2026: AI is doing even more heavy lifting for scammers. Voice cloning has made phone-based imposter scams harder to detect, and deepfake technology has made romance fraud and investment schemes more convincing. Data breaches are contributing to the rise in Reservation Hijacking Scams, while lookalike sites built to mimic real booking platforms, sportsbooks, and ticket sellers are surfacing through paid search ads, often indistinguishable from the real thing.

The Scam-Free Summer Forecast

Norton's threat intelligence team is tracking the scams hitting right now. Trending scams include:

Reservation hijack attacks that use your real hotel name, real dates, and real confirmation number to redirect your payment to a fake page. Fake ticket sites for sold-out concerts, festivals, or sports events like the World Cup that surface above the legitimate sellers in search results. AI-powered romance scams where the video chats look real (because they are, just not the person on the other end). Gambling sites built specifically for major sporting events, designed to disappear by September before anyone catches up. The forecast details 10 scams in total, each with the threat data behind the seasonal spike and the specific steps to avoid it. The full 2026 Summer Scam Forecast is available now at https://us.norton.com/blog/research/summer-scams.

How to Stay Safe
For consumers who want real-time protection against these threats, Norton Genie has them covered. Built directly into Norton Cyber Safety products, Genie analyzes texts,, emails, and websites for hidden scam patterns and detects sophisticated schemes even the most careful person can miss. Key features like Safe SMS, Safe Web, and Safe Email proactively flag suspicious content before it can do damage, while Safe Call automatically blocks scam calls. For those who do fall victim, Norton 360 with LifeLock Ultimate Plus also includes Scam Support and Reimbursement to help recover lost funds. You can also use Genie with the Norton App in ChatGPT.

Norton wishes everyone a Scam Free Summer and will be sharing additional threat intelligence, expert commentary, and consumer guidance throughout the season.

About Norton
Norton is a leader in Cyber Safety, and part of Gen (NASDAQ: GEN), a global company dedicated to powering Digital Freedom with a family of trusted consumer brands. Norton empowers millions of individuals and families with award-winning protection for their devices, online privacy, and identity. Norton products and services are certified by independent testing organizations including AV-TEST, AV Comparatives, and SE Labs. Norton is a founding member of the Coalition Against Stalkerware. Learn more at https://us.norton.com.

Media Contact:
Brittany Posey
Gen
[email protected]

SOURCE Gen Digital Inc.

Staar Surgical (STAA - Free Report) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company.

The upward trend in estimate revisions for this maker of implantable lenses reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- is principally built on this insight.

The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.

For Staar Surgical, strong agreement among the covering analysts in revising earnings estimates upward has resulted in meaningful improvement in consensus estimates for the next quarter and full year.

The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:

12 Month EPS

Current-Quarter Estimate RevisionsThe company is expected to earn $0.12 per share for the current quarter, which represents a year-over-year change of +123.1%.

Over the last 30 days, the Zacks Consensus Estimate for Staar Surgical has increased 57.14% because one estimate has moved higher compared to no negative revisions.

Current-Year Estimate RevisionsFor the full year, the company is expected to earn $0.59 per share, representing a year-over-year change of +837.5%.

There has been an encouraging trend in estimate revisions for the current year as well. Over the past month, one estimate has moved up for Staar Surgical versus no negative revisions. This has pushed the consensus estimate 28.57% higher.

Favorable Zacks RankThanks to promising estimate revisions, Staar Surgical currently carries a Zacks Rank #2 (Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.

Bottom LineStaar Surgical shares have added 9.5% over the past four weeks, suggesting that investors are betting on its impressive estimate revisions. So, you may consider adding it to your portfolio right away to benefit from its earnings growth prospects.

STAAR Surgical (STAA) expects Q1 net sales to exceed $90M, more than doubling year-over-year, driven primarily by China and double-digit growth in the Americas. Disney plans 1,000 job cuts in marketing overhaul under new CEO.